Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 November 2024 | Story Leonie Bolleurs | Photo Tania Allen
Business School Partnership 2024
Prof Per Assmo from University West, Sweden and Prof Anthea Rhoda from the UFS signed a Memorandum of Understanding that will develop academic cooperation across fields such as research, student and academic exchanges, and collaborative projects.

The University of the Free State (UFS) has signed a Memorandum of Understanding (MOU) with University West, Sweden. Held at the UFS Business School on the Bloemfontein Campus, the event saw the signing of the agreement by Prof Anthea Rhoda, acting UFS Vice-Chancellor and Principal, and Prof Per Assmo, Deputy Vice-Chancellor for Internationalisation at University West. The partnership aims to develop academic cooperation across fields such as research, student and academic exchanges, and collaborative projects.

This MOU opens the door to a wide range of collaborative initiatives, including academic and researcher exchanges for the purposes of teaching, conducting lectures, conducting research, and exchanging expertise. Additionally, the MOU includes student exchange programmes, joint research projects, and the shared hosting of seminars and conferences.

Prof Rhoda shared her enthusiasm to incorporate work-integrated learning (WIL) more widely at the UFS. “We are looking at work-integrated learning as an extension of engaged scholarship. It is something that we're looking forward to expanding,” she said.

Building a connected community

Prof Assmo explained that their institution, though small, has a unique approach that focuses on both production technology and work-integrated learning – a teaching model that goes beyond internships to provide students with practical, hands-on experience. "For us, WIL is a research field and academic discipline in its own right," he said.

University West is also the only university in the world to offer a PhD specifically in WIL, a programme it spent 20 years developing.

“We want to collaborate with South Africa as a strategic partner,” he said. The University West is already actively working with several South African universities, including the UFS, the Central University of Technology, the University of the Western Cape, and Tshwane University of Technology. “This would be the core for us, where we collaborate and find different forms within research and education, not restricted to any faculty or field as such.”

His vision also includes forming a larger ‘Nordic hub’ of connections across Sweden, Norway, and the European Union, along with a ‘regional hub’ in Bloemfontein. This way, universities can share ideas and resources to build a stronger, more connected community for the future.

A need for work-integrated learning

A working example of this partnership between University West and the UFS is the collaborative focus on integrated learning between Prof Liezel Massyn, Associate Professor in the UFS Business School, and Prof Kristina Areskoug Josefsson, Professor in Work-integrated Learning and Health Science from University West. They have a mutual commitment to improve educational practices through international partnerships and to advance integrated learning strategies. Together, they have already co-authored a research article and presented their findings at five conferences this year.

Prof Massyn said she realised that there is a need for work-integrated learning, specifically in the UFS Business School. “Initially, I thought our students were working, so they didn't need the work-integrated learning component. I then realised it could actually add a lot more value.”

Prof Nicolene Barkhuizen, Director of the UFS Business School, highlighted how this venture aligns with the university’s Vision 130, which aims to expand the UFS’ global footprint. “This partnership is an optimisation of the collaboration to contribute to Vision 130, expanding our reach globally while bringing practical value locally. We are looking forward to a very fruitful collaboration,” she said.

Speaking on behalf of the Faculty of Economic and Management Sciences, acting Dean Prof Frans Prinsloo discussed the potential for future projects. “Now that we have this collaboration agreement, there are many opportunities we can explore further,” he stated.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept